NCT01266499

A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).

A Randomized Open Label Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Rambam Health Care Campus · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Klebsiella pneumonia, inhabitant of the digestive tract, is a frequent nosocomial pathogen. It is currently the fourth most common cause of pneumonia and fifth most common cause of bacteremia in intensive care patients (1-3). The aim of the present randomized controlled trial is to assess the efficacy of non-absorbable oral antibiotics in the eradication of the KPC carrier state.

Conditions

• Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia

Interventions

Type	Name	Description
DRUG	Colistin (Polymyxin E) 100mg x 4/d	Colistin (Polymyxin E) 100mg x 4/d
DRUG	both medications	PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
DRUG	will not receive PO treatment	will not receive PO treatment - will receive plecebo treatment
DRUG	PO Garamycin 80mg x 4/d	PO Garamycin 80mg x 4/d

Timeline

• Start date: 2009-07-01
• Primary completion: 2011-01-01
• Completion: 2012-01-01
• First posted: 2010-12-24
• Last updated: 2017-04-28

Locations

1 site across 1 country: Israel